Company Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States.
The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.
It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Country | United States |
| IPO Date | Feb 3, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 711 |
| CEO | Frank D. Lee |
Contact Details
Address: 5401 West Kennedy Boulevard Tampa, Florida United States | |
| Website | https://www.pacira.com |
Stock Details
| Ticker Symbol | PCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001396814 |
| CUSIP Number | 695127100 |
| ISIN Number | US6951271005 |
| Employer ID | 51-0619477 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Frank D. Lee | Chief Executive Officer & Director |
| Daryl Gaugler | Chief Operating Officer |
| Shawn M. Cross | Chief Financial Officer |
| Anthony Molloy III, Esq. | Chief Legal & Compliance Officer |
| Charles A. Reinhart III, CPA, M.B.A. | Executive Officer |
| David M. Stack | Advisor |
| Dr. Jonathan Slonin M.D. | Chief Medical Officer |
| Kristen Williams J.D. | Chief Administrative Officer & Secretary |
| Lauren Bullaro Riker | Principal Accounting Officer & Senior Vice President of Finance |
| Susan Mesco | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | 8-K | Current Report |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 11, 2024 | DFAN14A | Filing |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |
| Nov 05, 2024 | 4 | Filing |